:Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemi
Genomic abnormalities, including del(17p)/TP53 mutation, del(11q), unmutated IGHV, and mutations in ...
The treatment landscape of chronic lymphocytic leukemia (CLL) has been challenged by the advent of n...
Chronic lymphocytic leukaemia is the most common lymphoproliferative disorder among adults in the W...
TP53-disrupted chronic lymphocytic leukaemia (CLL) patients show a suboptimal long-term response to ...
TP53 aberrations [del(17p) or TP53 mutation] predict poor survival with chemoimmunotherapy in patien...
Continous Treatment with Ibrutinib in 100 Untreated Patients with TP53 Disrupted Chronic Lymphocytic...
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristi...
A major revolution in the treatment of chronic lymphocytic leukemia (CLL) began with the approval of...
Ibrutinib blocks B-cell receptor signaling and interferes with leukemic cell-tomicroenvironment inte...
Abstract According to data presented at the 2017 American Society of Oncology (ASCO) Annual Meeting,...
The Bruton's tyrosine kinase inhibitor ibrutinib is a highly effective, new targeted therapy for chr...
The Bruton's tyrosine kinase protein is expressed in most hematopoietic cells with the exception of ...
Ibrutinib is a potent inhibitor of Bruton’s tyrosine kinase (BTK). Studies published in the New Engl...
Ibrutinib has demonstrated a significant clinical impact in patients with de novo and relapsed/refra...
Treatment of chronic lymphocytic leukemia (CLL) has shifted from chemo-immunotherapy to targeted age...
Genomic abnormalities, including del(17p)/TP53 mutation, del(11q), unmutated IGHV, and mutations in ...
The treatment landscape of chronic lymphocytic leukemia (CLL) has been challenged by the advent of n...
Chronic lymphocytic leukaemia is the most common lymphoproliferative disorder among adults in the W...
TP53-disrupted chronic lymphocytic leukaemia (CLL) patients show a suboptimal long-term response to ...
TP53 aberrations [del(17p) or TP53 mutation] predict poor survival with chemoimmunotherapy in patien...
Continous Treatment with Ibrutinib in 100 Untreated Patients with TP53 Disrupted Chronic Lymphocytic...
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristi...
A major revolution in the treatment of chronic lymphocytic leukemia (CLL) began with the approval of...
Ibrutinib blocks B-cell receptor signaling and interferes with leukemic cell-tomicroenvironment inte...
Abstract According to data presented at the 2017 American Society of Oncology (ASCO) Annual Meeting,...
The Bruton's tyrosine kinase inhibitor ibrutinib is a highly effective, new targeted therapy for chr...
The Bruton's tyrosine kinase protein is expressed in most hematopoietic cells with the exception of ...
Ibrutinib is a potent inhibitor of Bruton’s tyrosine kinase (BTK). Studies published in the New Engl...
Ibrutinib has demonstrated a significant clinical impact in patients with de novo and relapsed/refra...
Treatment of chronic lymphocytic leukemia (CLL) has shifted from chemo-immunotherapy to targeted age...
Genomic abnormalities, including del(17p)/TP53 mutation, del(11q), unmutated IGHV, and mutations in ...
The treatment landscape of chronic lymphocytic leukemia (CLL) has been challenged by the advent of n...
Chronic lymphocytic leukaemia is the most common lymphoproliferative disorder among adults in the W...